Neuropsychiatric side effects of efavirenz therapy (Q36762436)

16 August 2017

1 reference

title

Neuropsychiatric side effects of efavirenz therapy (English)

1 reference

16 August 2017

1 reference

1

Gabriele Arendt

1 reference

16 August 2017

Dominique de Nocker

2

1 reference

16 August 2017

Hans-Juergen von Giesen

series ordinal

3

1 reference

16 August 2017

Thorsten Nolting

series ordinal

4

1 reference

16 August 2017

language of work or name

English

0 references

publication date

1 March 2007

1 reference

Expert Opinion on Drug Safety

16 August 2017

published in

1 reference

16 August 2017

volume

6

1 reference

16 August 2017

issue

2

1 reference

16 August 2017

page(s)

147-154

1 reference

Neurospychiatric symptoms in HIV infected patients and the role of efavirenz

16 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.2.147

Neuropsychiatric effects of efavirenz: delayed onset

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.2.147

Therapeutic effects of nonnucleoside reverse transcriptase inhibitors on the central nervous system in HIV-1-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.2.147

L-743, 726 (DMP-266): a novel, highly potent nonnucleoside inhibitor of the human immunodeficiency virus type 1 reverse transcriptase

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.2.147

Pharmacokinetic drug interactions with non-nucleoside reverse transcriptase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.2.147

Efavirenz for HIV-1 infection in adults: an overview

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.2.147

Long-term safety and efficacy of NNRTI within the central nervous system

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.2.147

Long-term assessment of neuropsychiatric adverse reactions associated with efavirenz

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.2.147

Comparison of neuropsychiatric side effects in an observational cohort of efavirenz- and protease inhibitor-treated patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.2.147

Efavirenz versus nevirapine in current clinical practice: a prospective, open-label observational study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.2.147

Analyzing sleep abnormalities in HIV-infected patients treated with Efavirenz

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.2.147

Changes in sleep quality and brain wave patterns following initiation of an efavirenz-containing triple antiretroviral regimen

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.2.147

Recreational substance use and tolerance of efavirenz in HIV-1 infected patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.2.147

The pharmacokinetics of methadone in HIV-positive patients receiving the non-nucleoside reverse transcriptase inhibitor efavirenz

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.2.147

Impact of efavirenz on neuropsychological performance and symptoms in HIV-infected individuals

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.2.147

Factors associated with efavirenz discontinuation in a large community-based sample of patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.2.147

Management of sudden psychiatric disorders related to efavirenz

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.2.147

Central nervous system adverse effects with efavirenz: case report and review

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.2.147

Association between efavirenz and selected psychiatric and neurological conditions

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.2.147

Long-term neuropsychiatric disorders on efavirenz-based approaches: quality of life, psychologic issues, and adherence

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.2.147

Efavirenz induces depressive-like behaviour, increased stress response and changes in the immune response in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.2.147

Recurrence of post-traumatic stress disorder symptoms after initiation of antiretrovirals including efavirenz: a report of two cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.2.147

Switch from efavirenz to nevirapine associated with resolution of efavirenz-related neuropsychiatric adverse events and improvement in lipid profiles

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.2.147

Cortisol serum levels and their relationship to certain antiretroviral drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.2.147

Efavirenz plasma concentrations in HIV-infected patients: inter- and intraindividual variability and clinical effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.2.147

Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.2.147

Prediction of neuropsychiatric adverse events associated with long-term efavirenz therapy, using plasma drug level monitoring

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.2.147

The effect of baseline CD4 cell count and HIV-1 viral load on the efficacy and safety of nevirapine or efavirenz-based first-line HAART.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.2.147

Severe CNS side-effect and persistent high efavirenz plasma levels in a patient with HIV/HCV coinfection and liver cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.2.147

Influence of CYP2B6 polymorphism on plasma and intracellular concentrations and toxicity of efavirenz and nevirapine in HIV-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.2.147

Efavirenz intoxication due to slow hepatic metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.2.147

Population pharmacokinetics and effects of efavirenz in patients with human immunodeficiency virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.2.147

Phenotypic susceptibility to nonnucleoside inhibitors of virion-associated reverse transcriptase from different HIV types and groups

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.2.147

HIV-1 drug resistance in subjects with advanced HIV-1 infection in whom antiretroviral combination therapy is failing: a substudy of AIDS Clinical Trials Group Protocol 388.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.2.147

Hepatic but not intestinal CYP3A4 displays dose-dependent induction by efavirenz in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.2.147

Preliminary Data of a Prospective Study on Neuropsychiatric Side Effects After Initiation of Efavirenz

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.6.2.147

21 January 2018

Identifiers

DOI

10.1517/14740338.6.2.147

1 reference

16 August 2017

1 reference